FDA weight-loss supplement alert grows
This article was originally published in The Tan Sheet
Executive Summary
The agency is now warning consumers about 72 tainted weight-loss supplement products, including Herbal Xenicol, Slimbionic and Xsvelten. In a March 20 announcement, FDA also expanded its alert to include the unapproved active pharmaceutical ingredients fenproporex, fluoxetine, furosemide and cetilistat, which has shown similar effects to those of orlistat in investigational trials. FDA said it inspected companies involved in selling illicit products and may issue warning letters and initiate seizure actions due to firms' "inadequate responses to recall requests." The agency faced criticism about its inability to deter illegal activity in the weight-loss supplement market (1"The Tan Sheet" Feb. 2, 2009, p. 9)
You may also be interested in...
Weight-loss pills on recall
FDA finds sibutramine, an appetite suppressant and weight-loss drug, in products marketed as dietary supplements by Young You Corp. The Tarzana, Calif.-based company announced July 15 a voluntary recall of Slimbionic, One Weight Loss Pill, SlimDemand and Botanical Weight Loss products, all sold through the Internet and Young You's Weight Loss and Rejuvenation Center in Tarzana. Slimbionic was part of a mass FDA alert concerning numerous tainted weight-loss products expanded in March (1"The Tan Sheet" March 23, 2009, In Brief). Sibutramine is the active ingredient in the Rx obesity drug Meridia and may pose a risk to patients with a history of coronary artery disease or congestive heart failure, FDA warned
FDA Adulterated Weight-Loss Supplement Actions Lack Teeth – Attorney
Three recalls out of nearly 70 weight-loss supplements identified since late December as adulterated with undeclared prescription drug ingredients reflect a growing disregard for FDA's authority, says an attorney for the manufacturer of one of the recalled products
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.